Asset profile
ACC017
Small molecule
Evidence outlook · no controlled comparison
NCT06719310 · Infection, Human Immunodeficiency Virus
The lead study's design has limits that temper confidence (see the rationale below), and it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT06719310: The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 54 same-indication; 46 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ACC017: this drug | Phase 1/2 | Small molecule | HIV integrase | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Raltegravir (Isentress) | Approved | Small molecule | HIV integrase | ||
| VH4524184 | Phase 2 | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | ||
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | ||
| Fosamprenavir (Lexiva / Telzir) | Approved | Small molecule | HIV protease | ||
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 | ||
| Ibalizumab (Trogarzo) | Approved | Monoclonal antibody | CD4 receptor |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.